<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSCARNET" rxcui="33562">
<ATC code="J05AD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypocalcemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the calcemia and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AR07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together</COMMENT>
</INTERACTION>
</INTERACTIONS>
